Your browser doesn't support javascript.
loading
A Model-Based Method for Assessment of Salivary Gland and Planning Target Volume Dosimetry in Volumetric-Modulated Arc Therapy Planning on Head-and-Neck Cancer.
Zhang, Honglai; Cao, Yijian; Antone, Jeffrey; Riegel, Adam C; Ghaly, Maged; Potters, Louis; Jamshidi, Abolghassem.
Afiliación
  • Zhang H; Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, New York, USA.
  • Cao Y; Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, New York, USA.
  • Antone J; Zucker School of Medicine at Northwell/Hofstra, Hempstead, New York, USA.
  • Riegel AC; Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, New York, USA.
  • Ghaly M; Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, New York, USA.
  • Potters L; Zucker School of Medicine at Northwell/Hofstra, Hempstead, New York, USA.
  • Jamshidi A; Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, New York, USA.
J Med Phys ; 44(3): 201-206, 2019.
Article en En | MEDLINE | ID: mdl-31576068
ABSTRACT
This study examined the relationship of achievable mean dose and percent volumetric overlap of salivary gland with the planning target volume (PTV) in volumetric-modulated arc therapy (VMAT) plan in radiotherapy for a patient with head-and-neck cancer. The aim was to develop a model to predict the viability of planning objectives for both PTV coverage and organs-at-risk (OAR) sparing based on overlap volumes between PTVs and OARs, before the planning process. Forty patients with head-and-neck cancer were selected for this retrospective plan analysis. The patients were treated using 6 MV photons with 2-arc VMAT plan in prescriptions with simultaneous integrated boost in dose of 70 Gy, 63 Gy, and 58.1 Gy to primary tumor sites, high-risk nodal regions, and low-risk nodal regions, respectively, over 35 fractions. A VMAT plan was generated using Varian Eclipse (V13.6), in optimization with biological-based generalized equivalent uniform dose (gEUD) objective for OARs and targets. Target dose coverage (D 95, D max, conformity index) and salivary gland dose (D mean and D max) were evaluated in those plans. With a range of volume overlaps between salivary glands and PTVs and dose constraints applied, results showed that dose D 95 for each PTV was adequate to satisfy D 95 >95% of the prescription. Mean dose to parotid <26 Gy could be achieved with <20% volumetric overlap with PTV58 (parotid-PTV58). On an average, the D mean was seen at 15.6 Gy, 21.1 Gy, and 24.2 Gy for the parotid-PTV58 volume at <5%, <10%, and <20%, respectively. For submandibular glands (SMGs), an average D mean of 27.6 Gy was achieved in patients having <10% overlap with PTV58, and 36.1 Gy when <20% overlap. Mean doses on parotid and SMG were linearly correlated with overlap volume (regression R 2 = 0.95 and 0.98, respectively), which were statistically significant (P < 0.0001). This linear relationship suggests that the assessment of the structural overlap might provide prospective for achievable planning objectives in the head-and-neck plan.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2019 Tipo del documento: Article